Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Receives Average Recommendation of “Moderate Buy” from Brokerages

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) has been assigned an average rating of “Moderate Buy” from the seven brokerages that are presently covering the stock, MarketBeat reports. Two research analysts have rated the stock with a hold rating, four have issued a buy rating and one has issued a strong buy rating on the company.

Several brokerages have commented on BAYRY. DZ Bank raised Bayer Aktiengesellschaft from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, May 19th. Zacks Research raised Bayer Aktiengesellschaft from a “strong sell” rating to a “hold” rating in a research report on Friday, May 8th. UBS Group raised Bayer Aktiengesellschaft from a “neutral” rating to a “buy” rating in a research report on Monday, March 16th. Finally, Jefferies Financial Group raised Bayer Aktiengesellschaft to a “hold” rating in a research report on Friday, May 29th.

Bayer Aktiengesellschaft Stock Performance

OTCMKTS:BAYRY opened at $13.16 on Friday. The stock has a market cap of $51.72 billion, a P/E ratio of -20.56, a price-to-earnings-growth ratio of 3.61 and a beta of 0.59. The firm’s fifty day simple moving average is $10.94 and its 200 day simple moving average is $11.49. Bayer Aktiengesellschaft has a twelve month low of $7.19 and a twelve month high of $14.85. The company has a quick ratio of 0.70, a current ratio of 1.05 and a debt-to-equity ratio of 1.06.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) last announced its quarterly earnings data on Tuesday, May 12th. The company reported $0.79 EPS for the quarter, beating the consensus estimate of $0.64 by $0.15. The business had revenue of $15.73 billion during the quarter, compared to analyst estimates of $15.77 billion. Bayer Aktiengesellschaft had a positive return on equity of 17.61% and a negative net margin of 4.75%.Bayer Aktiengesellschaft has set its FY 2026 guidance at 1.200-1.346 EPS. As a group, research analysts predict that Bayer Aktiengesellschaft will post 1.25 EPS for the current year.

Bayer Aktiengesellschaft Company Profile

Bayer Aktiengesellschaft is a global life sciences company headquartered in Leverkusen, Germany, with a history dating back to 1863. The company operates across three principal business areas—Pharmaceuticals, Consumer Health and Crop Science—serving customers and markets worldwide. Bayer develops, manufactures and markets prescription medicines, over-the-counter healthcare products and agricultural solutions, and maintains research and development programs focused on new therapies and technologies in its core fields.

In Pharmaceuticals, Bayer focuses on prescription drugs across therapeutic areas such as cardiology, oncology, hematology and women’s health, supporting clinical development and regulatory activities for both marketed products and pipeline candidates.